The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase III trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma: A nationwide multicenter study in Japan

被引：0

作者：

Sakamoto, A. ^{[1
]}

Kurosaki, M. ^{[2
]}

Tsuchiya, K. ^{[2
]}

Abe, T. ^{[3
]}

Ogawa, C. ^{[4
]}

Soda, T. ^{[5
]}

Kimura, H. ^{[6
]}

Kondo, M. ^{[7
]}

Tsuji, K. ^{[8
,9
]}

Koichiro, F. ^{[10
]}

Shigeno, M. ^{[11
]}

Jyoko, K. ^{[12
]}

Narita, R. ^{[13
]}

Uchida, Y. ^{[14
]}

Yoshida, H. ^{[15
]}

Akahane, T. ^{[16
]}

Kobashi, H. ^{[17
]}

Mitsuda, A. ^{[18
]}

Marusawa, H. ^{[1
]}

Izumi, N. ^{[2
]}

机构：

[1] Osaka Red Cross Hosp, Gastroenterol, Osaka, Japan

[2] Musashino Res Cross Hosp, Gastroenterol, Tokyo, Japan

[3] Maehashi Red Cross Hosp, Gastroenterol, Maehashi, Japan

[4] Takamatsu Red Cross Hosp, Gastroenterol, Takamatsu, Kagawa, Japan

[5] Fukuoka Red Cross Hosp, Hepatol, Fukuoka, Fukuoka, Japan

[6] Kyoto Daiichi Red Cross Hosp, Gastroenterol, Kyoto, Japan

[7] Otsu Res Cross Hosp, Gastroenterol, Otsu, Shiga, Japan

[8] Hiroshima Res Cross Hosp, Gastroenterol, Hiroshima, Japan

[9] Atom Bomb Survivors, Hiroshima, Japan

[10] Masuda Red Cross Hosp, Gastroenterol, Masuda, Japan

[11] Nagasaki Genbaku Res Cross Hosp, Gastroenterol, Nagasaki, Japan

[12] Matsuyama Res Cross Hosp, Hepatobiliary & Pancreat Dis, Matsuyama, Ehime, Japan

[13] Oita Red Cross Hosp, Hepatol, Oita, Japan

[14] Matsue Red Cross Hosp, Gastroenterol, Matsue, Shimane, Japan

[15] Japanese Red Cross Med Ctr, Gastroenterol, Tokyo, Japan

[16] Ishinomaki Red Cross Hosp, Gastroenterol, Ishinomaki, Miyagi, Japan

[17] Okayama Red Cross Hosp, Gastroenterol, Okayama, Japan

[18] Tottori Red Cross Hosp, Gastroenterol, Tottori, Japan

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

752P

引用

页码：289 / 289

页数：1

共 50 条

[31] A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subject with unresectable hepatocellular carcinoma.
Finn, Richard S.
Cheng, Ann-Lii
Ikeda, Kenji
Kudo, Masatoshi
Tamai, Toshiyuki
Dutcus, Corina E.
Younger, Steven
Han, Kwang-Hyub
Qin, Shukui
Raymond, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[32] IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Vogel, A.
Saborowski, A.
Siegler, G. M.
Siebler, J.
Lindig, U.
Schultheiss, M.
Mueller, T.
Simon, H.
Joeckel, C.
Muller, D. W.
Al-Batran, S-E.
De Toni, E.
ANNALS OF ONCOLOGY, 2023, 34 : S598 - S598
[33] Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
Anthony B. El-Khoueiry
Tim Meyer
Ann-Lii Cheng
Lorenza Rimassa
Suvajit Sen
Steven Milwee
Robin Kate Kelley
Ghassan K. Abou-Alfa
BMC Cancer, 22
[34] A Phase III Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma (RCC)
Motzer, Robert J.
Grunwald, Viktor
Hutson, Thomas E.
Porta, Camillo
Powles, Thomas
Eto, Masatoshi
Dutcus, Corina
Baig, Mahadi A.
Dutta, Lea
Li, Di
Young, Louise
Choueiri, Toni K.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 169 - 169
[35] A Long-Term Study of Acotiamide in Patients With Functional Dyspepsia: Results From an Open-Labeled Phase III Trial in Japan on Safety and Efficacy
Matsueda, Kei
Hongo, Michio
Ushijima, Satoshi
Akiho, Hiraku
Kato, Hiruki
GASTROENTEROLOGY, 2011, 140 (05) : S805 - S805
[36] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, Ann-Lii
Kang, Yoon-Koo
Chen, Zhendong
Tsao, Chao-Jung
Qin, Shukui
Kim, Jun Suk
Luo, Rongcheng
Feng, Jifeng
Ye, Shenglong
Yang, Tsai-Sheng
Xu, Jianming
Sun, Yan
Liang, Houjie
Liu, Jiwei
Wang, Jiejun
Tak, Won Young
Pan, Hongming
Burock, Karin
Zou, Jessie
Voliotis, Dimitris
Guan, Zhongzhen
LANCET ONCOLOGY, 2009, 10 (01): : 25 - 34
[37] Efficacy and safety of transarterial chemoembolization alone compared to its combination with anlotinib among patients with intermediate or advanced stage hepatocellular carcinoma: a phase II randomized controlled trial
Zhang, Dinghu
Zhang, Zhewei
Luo, Jun
Zheng, Jiaping
Mao, Xiaochun
Tsilimigras, Diamantis I.
Chun, Ho Jong
Zeng, Hui
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04) : 1627 - 1635
[38] Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.
Li, Shaohua
Zhong, Chong
Li, Qiang
Zou, Jingwen
Wang, Qiaoxuan
Shang, Changzhen
Cheng, Yuan
Cao, Mingrong
Huang, Huakun
Mei, Jie
Lu, Lianghe
Zhao, Rongce
Lin, Wenping
Wen, Yuhua
Guo, Zhixing
Ling, Yihong
Zheng, Lie
Wei, Wei
Guo, Rongping
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
El-Khoueiry, Anthony B.
Meyer, Tim
Cheng, Ann-Lii
Rimassa, Lorenza
Sen, Suvajit
Milwee, Steven
Kelley, Robin Kate
Abou-Alfa, Ghassan K.
BMC CANCER, 2022, 22 (01)
[40] A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)
Motzer, Robert J.
Grunwald, Viktor
Hutson, Thomas E.
Porta, Camillo
Fowles, Thomas
Eto, Masatoshi
Dutcus, Corina E.
Baig, Mahadi Ali
Dutta, Lea
Li, Di
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →